Two cases of pathological complete response to neoadjuvant chemoradiation therapy in pancreatic cancer

Yoko Fujii-Nishimura, Ryo Nishiyama, Minoru Kitago, Yohei Masugi, Akihisa Ueno, Koichi Aiura, Shigeyuki Kawachi, Miho Kawaida, Yuta Abe, Masahiro Shinoda, Osamu Itano, Akihiro Tanimoto, Michiie Sakamoto, Yuko Kitagawa

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)


Neoadjuvant chemoradiation therapy (NACRT) is increasingly used in patients with a potentially or borderline resectable pancreatic ductal adenocarcinoma (PDA) and it has been shown to improve survival and reduce locoregional metastatic disease. It is rare for patients with PDA to have a pathological complete response (pCR) to NACRT, but such patients reportedly have a good prognosis. We report the clinicopathological findings of two cases of pCR to NACRT in PDA. Both patients underwent pancreatectomy after NACRT (5-fluorouracil, mitomycin C, cisplatin, and radiation). Neither had residual invasive carcinoma and both showed extensive fibrotic regions with several ducts regarded as having pancreatic intraepithelial neoplasia 3/carcinoma in situ in their post-therapy specimens. It is noteworthy that both patients had a history of a second primary cancer. They both had comparatively good outcomes: one lived for 9 years after the initial pancreatectomy and the other is still alive without recurrence after 2 years.

Original languageEnglish
Pages (from-to)26-31
Number of pages6
JournalKeio Journal of Medicine
Issue number2
Publication statusPublished - 2015 Jun 6


  • Neoadjuvant chemoradiation therapy
  • Pancreatic ductal adenocarcinoma
  • Pathological complete response

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Two cases of pathological complete response to neoadjuvant chemoradiation therapy in pancreatic cancer'. Together they form a unique fingerprint.

Cite this